CICipla500087Quarterly results

Q2FY27 results: income from operations INR 7,404 Cr, EBITDA margin 18.7%, PAT INR 878 Cr

Q2FY27 results released.

By ScoutQuest · Tue 27 Oct 2026, 1:39 PM IST · 2 min read

Income from operations

INR 7,404 Cr (Q2FY26: INR 7,589 Cr)

EBITDA / margin

INR 1,388 Cr, margin 18.7%

PAT

INR 878 Cr

The update encloses the company's press release on its unaudited consolidated financial results for the quarter ended September 30th, 2026, along with the announcement of the earnings conference call.

Quarter in numbers

• Income from operations came in at INR 7,404 Cr, compared with INR 7,589 Cr in the same quarter a year earlier.
• EBITDA was INR 1,388 Cr, equal to 18.7% of income from operations.
• Profit after tax was INR 878 Cr.
• The release describes the quarter as showing consistent sequential growth in revenue and EBITDA, with the EBITDA margin expanding quarter on quarter.

The release also carries a statement from the MD and Global CEO, Achingupta, noting progress across focused markets, the sequential revenue growth, the strong India business, and continued focus on productivity and pipeline.

Where the sales came from

• India (prescription, trade generics and Cipla Health) grew 12% year on year, which the release calls the highest quarterly sales for the business. Branded prescription is described as having grown in double digits in the market, led by respiratory, urology, cardiac, anti-diabetes and dermatology therapies. Trade generics saw new launches during the quarter, and consumer health brands Nicotex, Omnigel and Cipldine are stated to have held leadership positions in their segments.
• North America revenue was 19% lower year on year. The release notes a sequential improvement and a No. 1 rank in the overall U.S. Albuterol MDI market, and flags two developments: FDA approval of gAdvair Diskus, described as the first dry powder inhaler approval from the company's U.S. manufacturing network, and an exclusive partnership with Qilu Pharmaceutical for commercialisation of a Keytruda biosimilar.
• The One Africa business was lower year on year, with the South Africa private market business stated to have grown faster than the market and the prescription business holding its No. 2 position.
• Emerging Markets and Europe were broadly flat, in what the release calls a challenging environment marked by geopolitical uncertainties and market-specific headwinds.
• API and Others were lower year on year.

Balance sheet and cash

The company reported a net cash position of INR 9,823 Cr. The release states that debt primarily consists of lease liabilities and working capital requirements. Total equity, inventory, cash and cash equivalents, trade receivables, trade payables and goodwill are set out in the balance sheet table of the release.

What a retail investor may want to track

• The gap between India growth and the decline in North America, and whether the U.S. product pipeline and the biosimilar partnership change that trend.
• The margin trajectory, since EBITDA margin is a key driver of profit.
• The net cash position, which the company highlights as a strength of the balance sheet.

The company has scheduled an earnings conference call on 27th October 2026 at 1600 hrs IST, where the leadership team will discuss the performance and take questions.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev